Neridronate
Neridronate structure
|
Common Name | Neridronate | ||
|---|---|---|---|---|
| CAS Number | 79778-41-9 | Molecular Weight | 277.149 | |
| Density | 1.7±0.1 g/cm3 | Boiling Point | 600.1±65.0 °C at 760 mmHg | |
| Molecular Formula | C6H17NO7P2 | Melting Point | 245° | |
| MSDS | Chinese USA | Flash Point | 316.7±34.3 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Eur. J. Pharm. Biopharm. 76(1) , 120-6, (2010) Recognition of bone mineral by bisphosphonates is crucial to their targeting, efficacy, therapeutic and diagnostic applications, and pharmacokinetics. In a search for rapid and simple NMR approaches to assessing the bone recognition characteristics of bisphos... |
|
|
Intramuscular neridronate in postmenopausal women with low bone mineral density.
Calcif. Tissue Int. 83(5) , 301-7, (2008) Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramus... |
|
|
The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
Mini Rev. Med. Chem. 9(9) , 1052-63, (2009) Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil, a widely used immunosuppressant. Numerous studies have developed limited sampling strategies (LSSs) to predict MPA AUC in solid organ transplant recipients.To systematically review and... |
|
|
Neridronic acid for the treatment of bone metabolic diseases.
Expert Opin. Drug Metab. Toxicol. 5(10) , 1305-11, (2009) Neridronic acid (6-amino-1-idroxyesilidene-1,1-bisphosphonate) is a nitrogen-containing bisphosphonate licensed in Italy for the treatment of osteogenesis imperfecta and Paget's disease of bone. The pharmacodynamic profile is similar to that of other nitrogen... |
|
|
Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
Biomed. Pharmacother. 64(4) , 271-4, (2010) The aetiology of thalassemia major-induced osteoporosis is multifactorial. Up to now, bisphosphonates seem to be a promising therapy. Taurine is found in a high concentration in bone cells enhancing bone tissue formation and inhibiting bone loss. Recently we ... |
|
|
Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.
Acta Histochem. 109(5) , 397-402, (2007) Increased osteoclastic activity is observed in many osteopathic disorders - including postmenopausal osteoporosis, Paget's disease, primary bone tumours, lytic bone metastases, multiple myeloma and rheumatoid arthritis - that involve increased bone resorption... |
|
|
Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.
Calcif. Tissue Int. 89(1) , 21-8, (2011) In patients with primary hyperparathyroidism (PHPT) not suitable for surgical correction, a skeletal protection with bisphosphonates is considered a reasonable option, but the long-term effects after treatment discontinuation are not well known. Sixty postmen... |
|
|
Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis.
Rheumatol. Int. 28(5) , 495-8, (2008) Because of the increased incidence of tuberculosis (TB) in recent years, infective spondylitis is still a major problem in the world. In skeletal TB the spine is the most often involved and lumbosacral spine involvement is rare. Nowadays early diagnosis and n... |
|
|
Acute pseudogout following intravenous neridronate for osteoporosis.
J. Rheumatol. 37(5) , 1076, (2010)
|
|
|
Efficacy and safety of intravenous neridronate in pediatric bone loss associated to Crohn's disease: a case report.
Clin. Exp. Rheumatol. 27(1) , 165, (2009)
|